Drugs / Rifafour
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05686356 | Jul 2023 → Jan 2026 overdue | tuberculosis | The Aurum Institute NPC | Active not recruiting | No outcome recorded |
| Comparator or background therapy4 trials | ||||||
| Phase 2 | NCT04629378 Comparator | Aug 2020 → Jun 2021 | tuberculosis | TASK Applied Science | Completed | No outcome recorded |
| Phase 2 | NCT03882177 Background | Feb 2020 → May 2022 | pulmonary tuberculosis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT01691534 Comparator | Oct 2012 → Apr 2013 | pulmonary tuberculosis | Global Alliance for TB Drug Development | Completed | No outcome recorded |
| Phase 2 | NCT01498419 Comparator | Mar 2012 → Apr 2013 | pulmonary tuberculosis | Global Alliance for TB Drug Development | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rifafour | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01498419 ↗ |
| Route | Oral | “Rifafour was administered orally once daily for 8 weeks according to weight” NCT01498419 ↗ |